Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women

Journal of the National Cancer Institute

Volumn 101, Issue 1, 2009, Pages 48-60

  Gunter, Marc J ^a   Hoover, Donald R ^b   Yu, Herbert ^c   Wassertheil Smoller, Sylvia ^a   Rohan, Thomas E ^a   Manson, Joann E ^d   Li, Jixin ^b   Ho, Gloria Y F ^a   Xue, Xiaonan ^a   Anderson, Garnet L ^e   Kaplan, Robert C ^a   Harris, Tiffany G ^a   Howard, Barbara V ^f   Wylie Rosett, Judith ^a   Burk, Robert D ^a   Strickler, Howard D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GLUCOSE; INSULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; ESTRADIOL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

AGE FACTORS; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; ODDS RATIO; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 58549084793     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn415     Document Type: Article

References (65)

1. American Cancer Society. Cancer Facts and Figures 2008. Available at http://www.cancer.org/docroot/STT/stt-0.asp. Accessed October 2008.
2. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-527.
3. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention:international evaluation of the evidence. Eur J Cancer Prev. 2002;11(suppl 2):S94-S100.
4. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19):2091-2102.
5. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk:findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004;111(5):762-771.
6. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control. 2006;17(5):695-703.
7. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002;13(8):741-751.
8. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.
9. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol. 1982;59(6):680-686.
10. Lazarus R, Sparrow D, Weiss S. Temporal relations between obesity and insulin: longitudinal data from the Normative Aging Study. Am J Epidemiol. 1998;147(2):173-179.
11. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem. 2001;276(41):38023-38028.
12. Ish-Shalom D, Christoffersen CT, Vorwerk P, et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia. 1997;40(suppl 2):S25-S31.
13. Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst. 1981;67(1):51-56.
14. Shafie SM, Hilf R. Insulin receptor levels and magnitude of insulin-induced responses in 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Cancer Res. 1981;41(3):826-829.
15. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 1972;32(2):226-232.
16. Pugeat M, Crave JC, Elmidani M, et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol. 1991;40(4-6):841-849.
17. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev. 1987;8(2):132-141.
18. Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1361-1368.
19. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol. 2002;156(4):349-352.
20. Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control. 2002;13(4):307-316.
21. Verheus M, Peeters PH, Rinaldi S, et al. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;119(3):659-667.
22. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer. 2000;88(5):828-832.
23. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer. 2003;106(1):90-95.
24. Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci. 1984;19(4):297-352.
25. Chu NF, Spiegelman D, Rifai N, Hotamisligil GS, Rimm EB. Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men. Int J Obes Relat Metab Disord. 2000;24(9):1085-1092.
26. Zapf J, Schmid C, Froesch ER. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endocrinol Metab. 1984;13(1):3-30.
27. Lee AV, Lee D. Role of the IGF system in breast cancer proliferation and progression. Endocrinol Breast Cancer. 1999;11:187-203.
28. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med. 1997;3(10):1141-1144.
29. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins:biological actions. Endocr Rev. 1995;16(1):3-34.
30. Juul A, Holm K, Kastrup KW, et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab. 1997;82(8):2497-2502.
31. Renehan AG, Egger M, Minder C, O'Dwyer ST, Shalet SM, Zwahlen M. IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer. 2005;115(6):1006-1007; author reply 1008.
32. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353.
33. Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer. 2004;111(3):418-423.
34. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer. 2004;111(2):293-297.
35. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(1):2-19.
36. Rinaldi S, Peeters PH, Berrino F, et al. IGF-I, IGFBP-3 and breast cancer risk in women: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2006;13(2):593-605.
37. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(4):763-768.
38. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer. 2003;10(2):331-345.
39. The Women's Initiative Study Group Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
40. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9 suppl):S18-S77.
41. The Women's Health Initiative Scientific Resources Website. Available at http://www.whiscience.org/about/biospecimen.php. Accessed October 2008.
42. The SEER Program Code Manual. NIH Publication No. 92-1999. Cancer Statistics Branch, Surveillance Program, Division of Cancer Prevention and Control, National Cancer Institute, US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1992.
43. SEER Program: Comparative Staging Guide for Cancer, version 1.1. Washington, DC: US Department of Health and Human Services, Public Health Service. NIH Publication No. 93-3640.
44. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
45. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442-443.
46. Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer. 2001;91(5):736-739.
47. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008;68(1):329-337.
48. Prentice RL. A case-cohort design for epidemiologic studies and disease prevention trials. Biometrika. 1986;73:1-11.
49. World Health Organization Global Database on Body Mass Index. Available at http://www.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed October 2008.
50. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218-1226.
51. Rinaldi S, Key TJ, Peeters PH, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer. 2006;118(11):2832-2839.
52. Antoine PJ, Bertrand F, Auclair M, Magre J, Capeau J, Cherqui G. Insulin induction of protein kinase C alpha expression is independent of insulin receptor Tyr1162/1163 residues and involves mitogen-activated protein kinase kinase 1 and sustained activation of nuclear p44MAPK. Endocrinology. 1998;139(7):3133-3142.
53. White MF, Kahn C.R. Mechanisms of insulin action. In: Moller ED, editor. Insulin resistance. New York, NY: John Wiley and Sons; 1993:9-47.
54. Milazzo G, Giorgino F, Damante G, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992;52(14):3924-3930.
55. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990;50(1):48-53.
56. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol. 2005;229(1-2):161-173.
57. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 2002;63(4):317-332.
58. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 2001;8(3):197-209.
59. Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene. 2001;20(50):7318-7325.
60. Lee AV, Jackson JG, Gooch JL, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999;13(5):787-796.
61. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253.
62. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-1657.
63. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72(2):374-381.
64. Campagnoli C, Abba C, Ambroggio S, Peris C. Differential effects of progestins on the circulating IGF-I system. Maturitas. 2003;46(suppl 1):S39-S44.
65. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1995;4(6):649-654.